Key result
A loading dose of warfarin compared to did not increase the proportion of patients with a therapeutic INR on day five when requiring two consecutive measures.
Why the study?
Do specific warfarin loading doses or regimens improve time to stable INR and reduce adverse events in patients newly initiated on warfarin?
Systematic Review (n=1,340)
Do specific warfarin loading doses or regimens improve time to stable INR and reduce adverse events in patients newly initiated on warfarin?
There remains considerable uncertainty regarding the optimal loading dose (10 mg vs 5 mg) for warfarin initiation, though lower or age-adjusted doses appear more appropriate in elderly patients.
Answers are grounded in this paper and cite their sources.
10 mg warfarin loading does not hasten therapeutic INR by day 5 versus 5 mg; challenges higher-dose initiation and supports lower-dose optimization trials.
BACKGROUND: Selection of the right warfarin dose at the outset of treatment is not straightforward, and current evidence is lacking to determine the optimal strategy for initiation of therapy. METHODS: We included randomized controlled trials in patients commencing anticoagulation with warfarin, comparing different loading dose or different regimens.We searched Medline, EMBASE, the Cochrane Library and the NHS Health Economics Database up to June 2009. Primary outcomes were time to stable INR and adverse events. We summarised results as proportion of INRs in range from date of initiation and compared dichotomous outcomes using relative risks (RR) and calculated 95% confidence intervals (CIs). RESULTS: We included 11 studies of 1,340 patients newly initiated on warfarin. In two studies that used single INR measures, a loading dose of 10 mg compared to 5 mg led to more patients in range on day five. However, in two studies which measured two consecutive INRs, a loading dose of 10 mg compared to 5 mg did not lead to more patients in range on day five (RR = 0.86, 95% CI, 0.62 to 1.19, p = 0.37). Patients receiving a 2.5 mg initiation does took longer to achieve the therapeutic range, whilst those receiving a calculated initiation dose achieved target range 0.8 days quicker (4.2 days vs. 5 days, p = 0.007). More elderly patients receiving an age adjusted dose achieved a stable INR compared to the Fennerty protocol (48% vs. 22% p = 0.02) and significantly fewer patients on the age adjusted regimens had high out-of-range INRs. Two studies report no significant differences between genotype guided and 5 mg or 10 mg initiation doses and in the one significant genotype study the control group INRs were significantly lower than expected. CONCLUSION: Our review findings suggest there is still considerable uncertainty between a 10 mg and a 5 mg loading dose for initiation of warfarin. In the elderly, lower initiation doses or age adjusted doses are more appropriate, leading to less higher INRs. Currently there is insufficient evidence to warrant genotype guided initiation, and adequately powered trials to detect effects on adverse events are currently warranted.
No takes yet. Share an insight, caveat, or question.
Heneghan et al. (2010) conducted a systematic review in Patients commencing anticoagulation with warfarin (n=1,340). 10 mg warfarin loading dose vs. 5 mg warfarin loading dose was evaluated on Proportion of patients with therapeutic INR at day 5 (two consecutive INRs) (RR 0.86, 95% CI 0.62 to 1.19, p=0.37). A loading dose of warfarin compared to did not increase the proportion of patients with a therapeutic INR on day five when requiring two consecutive measures.
Synapse has enriched 10 related papers. Consider them for comparative context: